Douglas E. Paull, MD, MS and Paul N. Uhlig, MD, MPA
Risk managers can help patient-subjects and clinician-researchers make informed novel device implantation decisions in the absence of preclinical trial data.
Two physicians assert that pharmaceutical companies' sponsorship of clinical conferences for residents and physicians represent a conflict of interest.
Two physicians assert that pharmaceutical companies' sponsorship of clinical conferences for residents and physicians represent a conflict of interest.
The ethical questions surrounding the recruitment of patients for clinical trials become more complicated when the recruiting physicians receive financial benefits for each patient enrolled.
Murray Kopelow, chief executive of the Accreditation Council for Continuing Medical Education, discusses his organization's the new draft standards for commercial support of continuing medical education.
The financial generosity of the pharmaceutical industry to provide funding for medical education tempts a compromise of professional standards and ethics.
The ethical questions surrounding the recruitment of patients for clinical trials become more complicated when the recruiting physicians receive financial benefits for each patient enrolled.
In April 2002, many pharmaceutical companies adopted PhRMA code, an attempt to self-regulate the pharmaceutical industry's marketing to physicians and other health care professionals.